NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, News, & Analysis

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals declared that its Board of Directors has approved a share buyback plan on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 3.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings data on Monday, February, 4th. The biopharmaceutical company reported $2.14 earnings per share for the quarter, topping analysts' consensus estimates of $1.60 by $0.54. The biopharmaceutical company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a return on equity of 18.15% and a net margin of 1.88%. The firm's revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the business earned $1.48 earnings per share. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals issued an update on its FY19 earnings guidance on Monday, February, 4th. The company provided EPS guidance of $9.10-9.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.80. The company issued revenue guidance of $4.625-4.7 billion, compared to the consensus revenue estimate of $4.75 billion.Alexion Pharmaceuticals also updated its FY 2019 guidance to $9.10-9.30 EPS.

15 Wall Street analysts have issued 1-year price targets for Alexion Pharmaceuticals' shares. Their predictions range from $123.00 to $190.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $162.6429 in the next year. This suggests a possible upside of 23.9% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

News headlines about ALXN stock have been trending positive this week, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Some companies that are related to Alexion Pharmaceuticals include Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TAK), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY) and Shiseido (SSDOY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Allergan (AGN), Biogen (BIIB), Amgen (AMGN) and Visa (V).

Alexion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (11.81%), BlackRock Inc. (7.28%), Jennison Associates LLC (3.91%), Norges Bank (1.79%), Northern Trust Corp (1.30%) and Geode Capital Management LLC (1.20%). Company insiders that own Alexion Pharmaceuticals stock include Ann M Veneman, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Orbimed Advisors LLC, Temasek Holdings Private Ltd, Bank of New York Mellon Corp, American Century Companies Inc., Eaton Vance Management, State of Tennessee Treasury Department and Sound Shore Management Inc. CT. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, Indrani Lall Franchini, John J Orloff, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Norges Bank, Swedbank, Geode Capital Management LLC, Prudential PLC, Amundi Pioneer Asset Management Inc., Candriam Luxembourg S.C.A. and Iridian Asset Management LLC CT. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $131.31.

Alexion Pharmaceuticals has a market capitalization of $29.34 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.59 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe.

The official website for Alexion Pharmaceuticals is http://www.alexion.com.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]